Skip to content
Est. 1998 proudly celebrating our 27th year of championing American business
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

KAMADA LTD

$7.24 +0.98% NASDAQ: KMDA · 15-min delayed
  • Public · NASDAQ: KMDA
  • 462 employees
  • Founded 1990
$413.6MMarket cap
462Employees
KMDANASDAQ
2013IPO

About KAMADA LTD

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Market cap
$413.6M
NASDAQ: KMDA
$7.24 +0.98%

15-minute delayed · data by Polygon.io

Past year

$6.60 $9.31

52-week range

Market cap
$413.6M
Dividend yield
3.45%
Shares outstanding
57.1M
Open
Day range
Prev close
Volume
IPO date
May 31, 2013

Market data by Polygon.io · prices are 15-minute delayed

Auto-generated

At a glance

  • Trading 22% below its 52-week high.
  • Pays a dividend yielding about 3.45% annually.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review KAMADA LTD.

Write a review
Newsroom

News about KAMADA LTD

News & sentiment via Polygon.io

Explore

Similar companies

Browse all →